News Sentiment

NTRA sentiment intelligence

Natera Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 269.95 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

88/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-3.4% over one week, +27.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 88/100 classification
One-week reaction -3.4% Price reacting lower
Trend fit Trend active 27.3% over four weeks
Fair value 92.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 36
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 10
Investing.com 8
simplywall.st 5
Kavout | AI 3
Simply Wall Street 2
Investing.com Nigeria 2
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 45
Earnings 4
Regulatory and legal 2
Analyst action 2
Guidance 2
Balance sheet 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Simply Wall Street Direct company coverage

The Bull Case For Natera (NTRA) Could Change Following New Signatera JAMA Oncology Evidence On MRD-Guided Chemotherapy

Natera, Inc. recently announced the resignation of Monica Bertagnolli from its Board of Directors and reported new JAMA Oncology data for its Signatera MRD test. The study, from the GALAXY arm of CIRCULATE-Japan, indicates that Signatera can identify colorectal liver metastases p

Tone
Positive 65/100
Event
Market update
Published
16 Jul 2026 21:11
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Form 4 Natera Inc For: 15 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Natera Inc (NTRA) dated July 15. Form 4s disclose transactions by company insiders, indicating changes in their ownership of the company's stock. Natera Inc's stock is noted with a -2.72% change in the context of this

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 03:09
Source
Investing.com Nigeria
Investing.com Direct company coverage

Natera co-founder Sheena Jonathan sells $836,898 in stock

Natera co-founder and director Sheena Jonathan sold 3,150 shares of the company's common stock for a total of $836,898 on July 13, 2026, under a Rule 10b5-1 trading plan. The sale occurred while the stock was trading just below its 52-week high, and an InvestingPro analysis sugge

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 01:41
Source
Investing.com
Stock Titan Direct company coverage

Natera (NTRA) co-founder sells 3,150 shares under Rule 10b5-1 plan

Natera, Inc. co-founder Sheena Jonathan reported the sale of 3,150 shares of common stock on July 13, 2026, under a Rule 10b5-1 trading plan adopted in December 2025. The sales occurred at weighted-average prices between $262.7160 and $268.3870 per share. Following these transact

Tone
Negative 31/100
Event
Market update
Published
16 Jul 2026 01:41
Source
Stock Titan
ChartMill Direct company coverage

NATERA INC (NTRA) Stock Chart

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 00:14
Source
ChartMill
Stock Titan Direct company coverage

Rowan Emma Chapman (NASDAQ: NTRA) files Form 144 to sell shares

Rowan Emma Chapman, a security holder of Natera, Inc. (NTRA), has filed a Form 144 to sell 135 common shares with an indicated value of $37,100.70 through Morgan Stanley Smith Barney around July 15, 2026. This filing also references a previous sale of 2,964 common shares on June

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 Natera For: 15 July By Investing.com

This article announces the filing of Form 144 for Natera (NTRA) on July 15, 2026. Form 144 indicates an intent to sell restricted securities, which can be an important piece of information for investors tracking insider transactions. The company's stock symbol NTRA is mentioned w

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 14:42
Source
Investing.com Canada
Stock Titan Direct company coverage

NTRA (NASDAQ: NTRA) holder plans sale of 1,500 common shares

Jonathan Sheena, a holder of Natera, Inc. (NASDAQ: NTRA), has filed a Form 144 notice indicating his plan to sell 1,500 common shares. These shares, with an aggregate market value of $412,830.00, were originally acquired as founders shares on April 30, 2012, and are scheduled to

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 13:42
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Natera, Inc. – BX:NTRA

This article focuses on the enterprise value to EBITDA forward of Natera, Inc. (BX:NTRA). It appears to be a financial data point from TradingView, presented without additional detailed analysis or market commentary. The content provided is primarily navigational and copyright in

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:12
Source
TradingView
Stock Titan Direct company coverage

[144] Natera, Inc. SEC Filing

Natera, Inc. investor Jonathan Sheena has filed a notice to sell up to 9,450 shares of common stock through Charles Schwab & Co., Inc. The shares have an aggregate market value of $2,515,779.00. The notice also details a history of multiple common stock sales by Jonathan Sheena o

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 15:12
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Natera, Inc. – XETR:45E

This page from TradingView displays financial information for Natera, Inc. (XETR:45E), specifically focusing on its enterprise value to EBITDA forward. The content indicates that the market is closed with no recent trades and provides an overview of available financial tools and

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 21:40
Source
TradingView
Market source Direct company coverage

Natera (NTRA) Stock Still Looks Expensive After A Very Large Run

Natera (NTRA) stock has seen a significant 454.9% return over three years, yet its valuation presents a mixed picture. A Discounted Cash Flow (DCF) model suggests the stock is undervalued by 49.0% at $553 per share compared to its current price of $281.85, while market-based mult

Tone
Neutral 50/100
Event
Balance sheet
Published
11 Jul 2026 07:40
Source
Market source
Kavout | AI Direct company coverage

What's Driving Natera's Recent Stock Action and Insider Selling

Natera (NTRA), a genetic testing company, has shown strong growth and financial performance, fueled by its precision diagnostics in oncology. Despite significant insider selling, largely pre-planned under Rule 10b5-1, the company faces high valuation, persistent net losses, and a

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 00:09
Source
Kavout | AI
Simply Wall Street Direct company coverage

Is Natera (NTRA) Fully Valued As Signatera Wins EU IVDR Certification?

Natera (NTRA) recently secured Class C certification under the EU’s In Vitro Diagnostic Regulation for its Signatera cancer test, a significant regulatory achievement for long-term EU market access. The stock has seen substantial gains, with returns of 26.49% over 30 days, 46.01%

Tone
Positive 61/100
Event
Regulatory and legal
Published
10 Jul 2026 21:09
Source
Simply Wall Street
Market source Direct company coverage

Natera (NTRA) Signatera Data Shows Who Benefits From Chemotherapy After CRC Surgery

New data presented in JAMA Oncology and at the ESMO GI congress highlights Natera's Signatera test for guiding adjuvant chemotherapy decisions in colorectal cancer patients, particularly those with liver metastases. The findings provide insights into which patients benefit most f

Tone
Positive 72/100
Event
Market update
Published
10 Jul 2026 14:14
Source
Market source
Market source Direct company coverage

NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers

Natera's molecular residual disease (MRD) test, Signatera, has received Class C certification under the EU's In Vitro Diagnostic Regulation (IVDR) for multiple cancer types, including solid tumors. This certification is a significant milestone for Natera, strengthening its positi

Tone
Positive 75/100
Event
Market update
Published
10 Jul 2026 13:41
Source
Market source
Moomoo Direct company coverage

Natera Receives EU IVDR Certification for Signatera

Natera has announced that its Signatera molecular residual disease (MRD) test has received IVDR certification from the European Union. This certification allows Signatera to be marketed and sold as a CE-marked product in the EU for a broad range of solid tumor indications, demons

Tone
Positive 70/100
Event
Market update
Published
10 Jul 2026 07:40
Source
Moomoo
BioSpace Direct company coverage

Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

Natera, Inc. announced that its Signatera platform, a personalized molecular residual disease (MRD) test for solid tumors, has received Class C IVDR certification from the European Union. This certification, achieved under one of the world's most stringent regulatory frameworks,

Tone
Positive 72/100
Event
Regulatory and legal
Published
09 Jul 2026 12:13
Source
BioSpace
Investing.com Direct company coverage

Natera’s Signatera receives EU IVDR certification for MRD testing

Natera Inc. announced that its Signatera test has received Class C certification under the European Union’s In Vitro Diagnostic Regulation (IVDR), allowing its use for minimal residual disease testing across various cancer types. This certification, coupled with recent approvals

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 11:40
Source
Investing.com
Kavout | AI Direct company coverage

Natera's Insider Selling Spree: A Red Flag Amidst Robust Growth

Natera (NTRA) shows strong revenue growth but is experiencing significant insider selling, totaling $85.96 million in the last three months, despite analysts generally holding a bullish stance. While many sales are pre-planned 10b5-1 transactions for diversification and tax purpo

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 06:40
Source
Kavout | AI
Stock Traders Daily Direct company coverage

(NTRA) Volatility Zones as Tactical Triggers

This article provides a quantitative analysis of Natera Inc. (NASDAQ: NTRA), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines a lack of clear price positioning signals and notes no resistance levels above the current price, suggesting u

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 02:12
Source
Stock Traders Daily